GRADE Guidelines: 22. The GRADE approach for tests and strategies - from test accuracy to patient important outcomes and recommendations. by Schünemann, Holger J et al.
Accepted Manuscript
GRADE Guidelines: 22. The GRADE approach for tests and strategies - from test
accuracy to patient important outcomes and recommendations
Holger J. Schünemann, Reem A. Mustafa, Jan Brozek, Nancy Santesso, Patrick
M. Bossuyt, Karen R. Steingart, Mariska Leeflang, Stefan Lange, Tommaso Trenti,
Miranda Langendam, Rob Scholten, Lotty Hooft, Mohammad Hassan Murad, Roman
Jaeschke, Anne Rutjes, Jasvinder Singh, Mark Helfand, Paul Glasziou, Ingrid Arévalo
Rodriguez, Elie A. Akl, Jonathan J. Deeks, Gordon H. Guyatt, GRADE Working Group
PII: S0895-4356(17)31095-8
DOI: https://doi.org/10.1016/j.jclinepi.2019.02.003
Reference: JCE 9824
To appear in: Journal of Clinical Epidemiology
Received Date: 11 December 2017
Revised Date: 14 November 2018
Accepted Date: 4 February 2019
Please cite this article as: Schünemann HJ, Mustafa RA, Brozek J, Santesso N, Bossuyt PM, Steingart
KR, Leeflang M, Lange S, Trenti T, Langendam M, Scholten R, Hooft L, Murad MH, Jaeschke R, Rutjes
A, Singh J, Helfand M, Glasziou P, Rodriguez IA, Akl EA, Deeks JJ, Guyatt GH, GRADE Working
Group, GRADE Guidelines: 22. The GRADE approach for tests and strategies - from test accuracy to
patient important outcomes and recommendations, Journal of Clinical Epidemiology (2019), doi: https://
doi.org/10.1016/j.jclinepi.2019.02.003.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
GRADE series - JCE  
GRADE Guidelines: Diagnosis II                                               Version 20181113 
C:\pdfconversion\WORK\authordoc\Article 22 JCE series diagnosis 2 20181113 clean.docx  1 
C:\pdfconversion\WORK\authordoc\Article 22 JCE series diagnosis 2 20181113 clean.docx 
GRADE Guidelines: 22. The GRADE approach for tests and strategies - from test accuracy 
to patient important outcomes and recommendations 
Holger J Schünemann
1,2,3
, Reem A. Mustafa
1,4
, Jan Brozek
1,2,3
, Nancy Santesso
1,3
, Patrick M 
Bossuyt
5
, Karen R Steingart
6
, Mariska Leeflang
4
, Stefan Lange
7
, Tommaso Trenti
8
, Miranda 
Langendam
4
, Rob Scholten
9
, Lotty Hooft
9
, Mohammad Hassan Murad
10
, Roman Jaeschke
1,2
, 
Anne Rutjes
11
, Jasvinder Singh
12
, Mark Helfand
13
, Paul Glasziou
14
, Ingrid Arévalo Rodriguez
15
, 
Elie A. Akl
16
, Jonathan J Deeks
17
, Gordon H Guyatt
1,2
 for the GRADE Working Group 
1. Department of Health Research Methods, Evidence, and Impact, 1280 Main Street West, 
McMaster University, Hamilton, Ontario L8S4K1, Canada  
2. Department of Medicine, 1280 Main Street West, McMaster University, Hamilton, 
Ontario L8S4K1, Canada 
3. McMaster GRADE centre, 1280 Main Street West, McMaster University, Hamilton, 
Ontario L8S4K1, Canada 
4. Department of Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA 
5. Clinical Epidemiology and Biostatistics and Bioinformatics Academic Medical Center, 
University of Amsterdam, Meibergdreef 9, Room J1b-209, P.O.Box 227001100 DE, 
Amsterdam, The Netherlands 
6. Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine, Liverpool, L3 
5QA, UK, Tel: +1 646 2439043 
7. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen/Institute for Quality and 
Efficiency in Health Care (IQWiG), Im Mediapark 8, 50670 Köln, Germany Cologne, Germany 
8. Azienda Ospedaliera Universitaria e Azienda USL di Modena, Nuovo Ospedale S. Agostino 
Estense, Via Giardini 1355  41126 Modena Italy 
9. Cochrane Netherlands/Julius Center for Health Sciences and Primary Care, University 
Medical Center Utrecht, P.O. Box 85500, 3508GA Utrecht, The Netherlands 
10. Division of Preventive Medicine, Mayo Clinic, 200 1
st
 ST. SW, Rochester, MN, 55902 
11. Clinical Trial Unit (CTU) Bern, Institute of Primary Health Care; Institute of Social and 
Preventive Medicine, University of Bern, Switzerland 
12. Medicine Service, VA Medical Center, Birmingham, AL, and Department of Medicine, 
University of Alabama at Birmingham, 510, 20th Street South, FOT805B, Birmingham, AL, 
USA 
13. Oregon Evidence-based Practice Center, Oregon Health & Science University, Portland 
VA Medical Center, Portland, Oregon 
14. CREBP, Faculty Health Science & Medicine, Bond University, Gold Coast, Qld 4229 
15. Clinical Biostatistics Unit, Ramón y Cajal Hospital (IRYCIS), Madrid, Spain and Division of 
Research, Fundación Universitaria de Ciencias de la Salud, Hospital de San José/ Hospital 
Infantil de San José, Bogotá, Colombia. 
16. Test Evaluation Research Group, Institute of Applied Health Research, University of 
Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
GRADE series - JCE  
GRADE Guidelines: Diagnosis II                                               Version 20181113 
C:\pdfconversion\WORK\authordoc\Article 22 JCE series diagnosis 2 20181113 clean.docx  2 
C:\pdfconversion\WORK\authordoc\Article 22 JCE series diagnosis 2 20181113 clean.docx 
17. Department of Internal Medicine, American University of Beirut, Riad-El-Solh Beirut, 
Beirut 1107 2020, Lebanon. 
 
 
Email addresses: 
Holger J Schünemann <schuneh@mcmaster.ca>; Reem Mustafa <ramustafa@gmail.com>; 
Brozek, Jan <brozekj@mcmaster.ca>; Nancy Santesso <santesna@mcmaster.ca>; Patrick 
Bossuyt <p.m.bossuyt@amc.uva.nl>; Karen Steingart < karenst@uw.edu >; Mariska Leeflang 
<m.m.leeflang@amc.uva.nl>; Stefan Lange <stefan.lange@iqwig.de>; Tommaso Trenti 
<t.trenti@ausl.mo.it>; Rob Scholten < R.J.P.Scholten@umcutrecht.nl >; Jasvinder Singh 
<Jasvinder.Singh@ccc.uab.edu>; Miranda Langendam <m.w.langendam@amc.uva.nl>; Lotty 
Hooft < L.Hooft@umcutrecht.nl>; Mohammed Hassan Murad 
<Murad.mohammad@mayo.edu>; Roman Jaeschke <jaeschke@mcmaster.ca>; Rutjes 
<anne.rutjes@ispm.unibe.ch>; Mark Helfand <helfand@ohsu.edu>; Paul Glasziou < Paul 
Glasziou <pglaszio@bond.edu.au>; Ingrid Arévalo Rodriguez <inarev7@yahoo.com>; Jon 
Deeks j.deeks@bham.ac.uk; Elie A Akl <ea32@aub.edu.lb>; Gordon Guyatt 
<guyatt@mcmaster.ca>;
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
GRADE series - JCE  
GRADE Guidelines: Diagnosis II                                               Version 20181113 
C:\pdfconversion\WORK\authordoc\Article 22 JCE series diagnosis 2 20181113 clean.docx 3 
C:\pdfconversion\WORK\authordoc\Article 22 JCE series diagnosis 2 20181113 clean.docx 
Address for correspondence: 
Holger J. Schünemann, MD, PhD, MSc  
Chair, Department of Clinical Epidemiology & Biostatistics 
Professor of Clinical Epidemiology and Medicine     
Department of Clinical Epidemiology and Biostatistics 
McMaster University, HSC Room 2C16                                         
1280 Main Street West Hamilton, ON   L8S 4K1  
Canada  
Tel: +1 905-525-9140 x 24931                                                                   
Email: schuneh@mcmaster.ca 
 
 
Word count:   4367 
Boxes: 1 
Tables:  3 
Figures: 5 
 
 
  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
GRADE series - JCE  
GRADE Guidelines: Diagnosis II                                               Version 20181113 
C:\pdfconversion\WORK\authordoc\Article 22 JCE series diagnosis 2 20181113 clean.docx 4 
C:\pdfconversion\WORK\authordoc\Article 22 JCE series diagnosis 2 20181113 clean.docx 
Highlights 
GRADE has developed and applied a comprehensive framework to evaluate the certainty of 
the evidence when direct evidence of the effect of testing on outcomes is not available and 
linked evidence that connects test accuracy to downstream consequences is required for 
decision-making. Ideally, this linked evidence comes from systematic reviews is that informs 
analytical frameworks for questions related to tests. 
What this adds to what is known? 
Application of GRADE’s approach requires guideline developers to rate their certainty in 
each element of the linked evidence that is required for decision-making.  
What are the implications, what should change now? 
Further research should address ways to arrive at, for each critical or important outcome 
and across outcomes, ratings of the certainty derived from the linked sources of evidence. 
This will often require formal modelling and assessing the certainty in the models. 
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Abstract: 
Objectives: This article describes GRADE’s framework of moving from test accuracy to 
patient or population important outcomes. We focus on the common scenario when studies 
directly evaluating the effect of diagnostic and other tests or strategies on health outcomes 
are not available or are not providing the best available evidence.  
Study Design and Setting: Using practical examples, we explored how guideline developers 
and other decision makers can use information from test accuracy to develop a 
recommendation by linking evidence that addresses downstream consequences.  Guideline 
panels should develop an analytic framework that summarizes the actions that follow from 
applying a test, and the consequences.  
Results: We describe GRADE’s current thinking about the overall certainty of the evidence 
(also known as quality of the evidence or confidence in the estimates) arising from 
consideration of the often complex pathways that involve multiple tests and management 
options. Each link in the evidence can – and often does - lower the overall certainty of the 
evidence required to formulate recommendations and make decisions about tests. The 
frequency with which an outcome occurs and its importance will influence whether or not a 
particular step in the linked evidence is critical to decision-making.  
Conclusions: Overall certainty may be expressed by the weakest critical step in the linked 
evidence. The linked approach to addressing optimal testing will often require the use of 
decision analytic approaches. We present an example that involves decision modeling in a 
GRADE Evidence to Decision framework for cervical cancer screening. However, since 
resources and time of guideline developers may be limited, we describe alternative, 
pragmatic strategies for developing recommendations addressing test use.   
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GRADE Guidelines: 22. The GRADE approach for tests and strategies - from test accuracy 
to patient important outcomes and recommendations 
 
1. Introduction 
Two previous articles in this series describe how systematic review authors and guideline 
developers develop GRADE Evidence to Decision Frameworks and assess their certainty of a 
body of evidence (also referred to as confidence in estimates or quality of evidence) 
evaluating tests, test strategies, management and downstream consequences.(1)(add 
reference to article 1) We focused on applying GRADE to accuracy  studies but did not 
describe how different bodies of evidence are linked and how to rate the overall certainty of 
the evidence.  Prior work on this topic has dealt with issues such as causal pathways in 
answering questions about tests, analytic frameworks and the importance of considering 
health outcomes for decision-making.(2-7) In the present article we focus on GRADE’s 
operationalization of linking information from accuracy studies to important outcomes 
when investigations directly evaluating the effect of diagnostic or other tests and related 
strategies on important outcome are unavailable. We will describe the conceptual issues of 
how guideline developers can move from the linked evidence that connects test accuracy to 
downstream management and consequences, and certainty of that evidence, to 
recommendations regarding the use of diagnostic and other tests use for the purpose of 
screening, monitoring and surveillance. With this work we are expanding on GRADE’s 
approach to rating the certainty of evidence for questions about tests.(5) 
 
The first part of the article will describe the judgments about the certainty we can place in 
the linked evidence between test accuracy and important outcomes. GRADE considers 
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accuracy a surrogate marker that requires further evaluation of the related consequences, 
including management decisions and consequent health outcomes. In particular, our 
framework will show  why guideline panels and other decision makers should usually be 
cautious when they use evidence of test accuracy as the basis for recommendations or 
decision. This caution is necessary because decision-making requires a review of and 
judgements about the evidence that links the evidence regarding accuracy to patient or 
population-important outcomes. 
 
The second part of the article focuses on the criteria that are involved in moving from 
evidence to a recommendation or decision using examples from guidelines that have 
applied this approach to diagnostic tests and strategies.(1) These examples, which expand 
on explanations previously provided regarding EtD frameworks, make clear that optimal 
insight into the consequences of alternative diagnostic strategies will often require full 
decision analytic modelling.(1)   
 
Decision analytic modelling, often undertaken when evidence is limited and use of expert 
estimates is necessary, involves constructing a decision tree and then forecasting based on 
probabilities of possible outcomes.  The objective of a decision analysis is to discover the 
most advantageous alternative under the defined conditions. We will provide an example of 
using decision analysis to model the relation between test accuracy, treatment strategies 
and health outcomes.   
 
In many situations, however, limited guideline resources and time mandate other, less 
sophisticated approaches.  Less sophisticated approaches are also desirable when the 
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correct decision or recommendation is evident without a full decision analysis. Therefore, 
we will present examples of less resource-intensive pragmatic approaches. We will conclude 
by summarizing challenges and suggestions for future work.  
 
2.0 What evidence is needed to make deductions about effects on patient outcomes? 
The GRADE approach to recommendations regarding test use involves balancing the 
desirable and the undesirable consequences (including non-health related consequences 
such as resource utilization and impact on equity).(1, 8-10) As they apply GRADE to 
recommendations about tests, guideline panelists will recognize that a division between 
testing and therapy or treatment is artificial. Figure 1 highlights that testing, including for 
diagnosis, screening and monitoring, demands interventions that become part of the overall 
strategy to management and that have consequences that require consideration.(5) The 
interventions that follow from test results may include observation of people or patients 
when no further action is required or possible.  
 
Guideline panels should develop an analytical framework that clarifies the interventions that 
follow from applying a test, and their consequences. (1, 7) Figure 2 provides a simplified and 
generic example of such a framework applied to a screening intervention.(11) The ideal 
body of evidence would include studies that directly compare the test strategies under 
consideration (i.e. randomized trials) and the resulting interventions and consequences (i.e. 
patient-important outcomes).  Such studies would, by design, address all of the issues in the 
analytical framework, and allow guideline panelists to apply the familiar GRADE approach 
for interventions articulated in detail in previous articles in this series.  For most tests or test 
and treat strategies, however, this direct evidence does not exist.(12)  
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Figure 3 describes the analytical framework including the health care pathways from a 
World Health Organization guideline addressing screening and treatment of cervical 
intraepithelial neoplasia (CIN stage 2 or 3), a precursor for cervical cancer, in low and middle 
resource countries (Box 1, example 1).  Using a detailed and structured process, the 
guideline panel, comprising experts from various disciplines, considered two screening 
options: human papilloma virus detection (HPV) or visual inspection with acetic acid (VIA), 
and the possible subsequent treatment options.(13-15)  
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Box 1. 
Example 1: Guideline determining population important outcomes and modeling to estimate benefits and harms   
In women at risk for cervical intraepithelial neoplasia (CIN) stage 2 to 3 in low and middle-income settings, what is the impact of testing for 
presence of HPV instead of VIA followed by management on patient and population important outcomes?(13)  
Population: women at risk of cervical cancer in low and middle-income countries 
Intervention: one time screening and treatment for CIN 2-3 
Comparison: no screening and treatment program 
Purpose and role of test: diagnosis and replacement  
Health outcomes: modeled estimates of death from cervical cancer, cervical cancer incidence, CIN 2-3 recurrence, major bleeding, 
premature delivery, infertility, major and minor infections, unnecessary treatment, cervical cancer detection during screening 
 
Recommendations: Where resources permit, the expert panel suggests a strategy of screen with an HPV test and treat with cryotherapy 
(or LEEP when not eligible for cryotherapy) over a strategy of screen with VIA and treat with cryotherapy (or LEEP when not eligible) 
(conditional recommendation, ⊕⊝⊝⊝ very low certainty evidence) 
In resource-constrained settings, where screening with an HPV test is not feasible, the expert panel suggests a strategy of screen with VIA 
and treat with cryotherapy (or LEEP when not eligible) over a strategy of screen with an HPV test and treat with cryotherapy (or LEEP when 
not eligible) (conditional recommendation, ⊕⊝⊝⊝ very low certainty evidence). 
Rationale: The benefits of screen-and-treat with an HPV test or VIA, compared to no screening, outweighed the harms, but the reductions 
in cancer and related mortality were greater with an HPV test when compared to VIA. The availability of HPV testing is resource-
dependent and, therefore, the expert panel suggests that an HPV test over VIA be provided where it is available, affordable, 
implementable, and sustainable over time. 
 
 
Example 2: Guideline using detailed case scenarios and simple modeling   
In patients suspected of cow’s milk allergy (CMA), what is the impact of using skin prick tests rather than an oral food challenge with cow’s 
milk on the diagnosis and management of IgE-mediated CMA?(16, 17)  
Population: patients suspected of CMA 
Intervention: skin prick test 
Comparison: no skin prick test before or after oral food challenge 
Purpose and role of test: diagnosis and replacement or add on 
Health outcomes: described as scenarios. For example, consequences of true positives were described as “The child will undergo oral food 
challenge that will turn out positive with risk of anaphylaxis, albeit in controlled environment; burden on time and anxiety for family; 
exclusion of milk and use of special formula. Some children with high pretest probability of disease and/or at high risk of anaphylactic 
shock during the challenge will not undergo challenge test and be treated with the same consequences of treatment as those who 
underwent food challenge. 
Recommendation: In settings where oral food challenge is considered a requirement for making a diagnosis of IgE-mediated CMA, we 
recommend using oral food challenge with cow’s milk as the only test without performing a skin prick test as a triage 
or an add-on test to establish a diagnosis (strong recommendation, low certainty of the evidence).  
Rationale: No additional benefit for patient outcomes, no need to do other testing if the reference test is performed regardless.  
 
 
Example 3: Guideline using case example for modeling and considering the possible consequences explicitly but no case scenarios or 
impact on health outcomes modeled 
In patients suspected of having pulmonary tuberculosis (TB), what is the impact of commercial serological tests for TB rather than 
conventional tests such as smear microscopy?(18) 
Population: patients suspected of having pulmonary tuberculosis 
Intervention: serological testing  
Comparison: sputum microscopy 
Purpose and role of test: diagnosis and replacement 
Health outcomes: a case study linking the test accuracy data to active tuberculosis in India showed that replacing sputum microscopy with 
serological testing would result in an estimated 14,000 additional cases of TB diagnosed but also result in 121,000 additional false-positive 
diagnoses relative to microscopy.  
 
Recommendation: … recommended that these tests should not be used in individuals suspected of active pulmonary or extra-pulmonary 
TB (strong recommendation).  
Rationale: The panel considered the consequences of false positives as unacceptable in balance with the possible benefits of detecting 
additional cases of TB. The overall harms far outweigh any potential benefits. 
 
For instance, only some lesions are amenable to cryotherapy. If lesions are not, possible 
therapeutic interventions include cold knife conization or loop electrosurgical excision 
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procedure (LEEP). The panel considered the possible outcomes – including benefits and 
harms - likely to result from each of the possible screen and treat pathways.  
 
Figure 4 describes the sequential steps that are important when assessing the certainty of 
evidence following the consequences of testing and treating.  Having formulated the 
question focusing on patient important outcomes and having concluded that direct 
evidence addressing these outcomes does not exist, the approach begins with an 
assessment of test accuracy (step 1). It proceeds to assessing the important consequences 
that may arise from applying the competing tests or diagnostic strategies and the evidence 
that links test results to those consequences (step 2). 
 
Returning to the example of the cervical screening guidelines, in which direct evidence for 
patient important outcomes is unavailable, step 1 included a systematic review of the body 
of evidence describing the performance of the two screening tests against a reference 
standard. The authors of the systematic review conducted a meta-analysis to obtain 
summary estimates of the sensitivity and specificity of the two screening tests.(15) The 
resulting pooled sensitivity of 95% (95% CI: 84 to 98) and pooled specificity 84% (95% CI: 72 
to 91) for HPV, and pooled sensitivity of 69% (95% CI: 54 to 81) and a pooled specificity of 
87% (95% CI: 79 to 92) for VIA, was based on five studies that compared both tests against a 
reference standard.  
 
Applying these summary statistics to the best estimates of the pretest probability of the 
target population (assumed here to be 2%) informed estimates of the number of test 
positives (true positives and false positives) and test negatives (true negatives and false 
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negatives).  For example, 1.9% (19 per 1000 women or 95% of 2%) in the HPV and 1.4% (14 
per 1000 women or 69% of 2%) in the VIA group would be true positives.  Although HPV’s 
accuracy is clearly superior (much better sensitivity with similar specificity) the considerably 
greater cost of HPV required estimating the magnitude of effect of alternative test 
strategies on patient-important outcomes (i.e. are the benefits at varying levels of pre-test 
probability worth the costs, in particular for country wide screening programs in low and 
middle-income countries).    
 
Step 2 involved linking these test outcomes to the anticipated important outcomes.  The 
panel used both a literature review and the experience of a multidisciplinary panel to 
provide information about the outcomes women may experience. Women with a positive 
test, suggesting the presence of CIN 2-3, would undergo further management with one of 
the possible therapies to reduce the risk of cervical cancer. Each treatment is associated 
with a probability of cure and a probability of adverse effects.  Those undergoing the 
procedures would, however, include not only those with CIN 2-3 (true positives) but also 
women without CIN 2-3 (false positives), and both groups would experience the adverse 
consequences, the latter without experiencing the benefits.  
 
Women with a negative test result, including those with a false negative test result and the 
attendant risk of CIN 2-3 developing into cervical cancer, would undergo only further 
observation.  Although this model ignores the possibility of repeating the screening test, in 
some settings - such as low and middle-resource countries - women may undergo only a 
single screening test and not return for further testing.  This makes the model suitable for 
those situations in which women are not repeatedly screened.  
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Estimates of treatment effects, both beneficial and harmful, and natural history should, 
ideally, come from systematic reviews of the relevant evidence.(13) For example, just as the 
efficacy of cryotherapy should be evaluated with a systematic review, so should the risk of 
developing cervical cancer in untreated CIN 2-3 (the natural history of the disease that 
determines the outcomes of false negatives). The systematic review determining the 
efficacy of cryotherapy reported a 61% relative risk reduction based on observational data 
(19) and the evidence addressing the natural history suggested a 2% progression to cervical 
cancer over 30 years.(14, 20) 
 
Turning to a different example (Box 1, example 2), for a recommendation addressing the use 
of skin prick testing for cows’ milk allergy (CMA), a condition affecting between 2 and 5% of 
children, the guideline panel evaluated the possible benefits and downsides on the basis of 
case examples using semi-quantitative information. (21, 22) For instance, in order to 
understand the consequences associated with the 264 per 1000 false negative skin prick 
tests in a population with a high pretest probability of CMA, guideline panel members 
received and reviewed typical case scenarios:  
i) The child suspected of CMA will be allowed to return home and will have an 
allergic reaction (possibly anaphylactic) to cow’s milk at home; high parental 
anxiety and reluctance to introduce future foods following the reaction; may lead 
to multiple exclusion diet.  
ii) The real cause of symptoms (i.e. CMA) will be missed leading to unnecessary 
investigations and treatments.   
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The panel developed these case scenarios, the baseline risk and the possible consequences, 
on the basis of a review of the literature and information obtained from allergists with 
experience in caring for affected patients. 
 
In another guideline (Box 1, example 3), a WHO guideline panel considered the 
consequences of applying a commercial serological tests sensitivity of 59% and specificity of 
91% in a population with a 10% risk of pulmonary tuberculosis: the test results in 41 per 
1000 false negatives and 81 per 1000 false positives. (18) Guideline panel members applied 
existing evidence synthesized in tuberculosis treatment guidelines to link the treatment 
efficacy and possible detrimental effects from delayed diagnosis, confusing other 
respiratory diseases (such as pneumonia) with pulmonary TB and resulting death from 
another disease, adverse drug reactions and unnecessary consumption of health care and 
patient resources. Panel members also reviewed a model describing the results in terms of 
true and false positive and true and false negatives of serological testing compared against 
other TB testing modalities (sputum smear and culture), including sensitivity analyses.  The 
information facilitated understanding of the effects in terms of unnecessarily treated and 
stigmatized patients and those appropriately treated. 
 
 
3.0 How should guideline panels rate the certainty of the evidence on health outcomes  
Preferably, guideline developers will evaluate and rate a body of evidence for each 
component of the linked evidence required for decision-making. Ideally, the evidence 
synthesis will be based on a systematic review (Figure 5).  
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3.1 Rating certainty in the estimates of test accuracy  
As described in the prior article, when direct evidence about important health outcomes is 
not available or associated with low certainty, GRADE begins by assessing the certainty of 
the estimates of the accuracy of the competing diagnostic strategies.(reference to article 1)  
We also clarified the roles of tests and how to interpret accuracy in the comparison of a new 
against an existing test. The systematic review of HPV and VIA reported high certainty in the 
test sensitivity, but important inconsistency in the specificity estimates across the 5 eligible 
studies yielding an overall certainty rating of moderate for specificity (Table 1).(15)  In 
previous articles we also introduced the three layers of SoF Tables for questions about the 
use of tests.(add reference to article dx 1)(23) Layer 1 and 2 SoF Tables , described in the 
previous article, do not consider the directness of the relation between test accuracy and 
health outcomes; here we focus on the third layer that considers the directness of the 
relation between test accuracy and health outcomes. 
 
3.2 Rating the certainty in linked evidence – directness of the health outcomes 
Here, we consider the assessment of the certainty of the evidence for a question involving 
tests for which direct evidence of effect on important outcomes is not available. In an ideal 
situation, rating the body of evidence should consider, for each important or critical 
outcome, the certainty of evidence from each linked element. In other words, assessing the 
linked evidence completes the assessment of how directly test accuracy estimates relate to 
the outcomes and informs the ratings of GRADE’s indirectness domain.  
 
For example, uncertainty regarding the estimates of the pretest probability or baseline risk 
used to calculate the test results in Table 1 will influence the overall rating of the certainty 
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(Figure 4, step 1).  Application of GRADE for prognostic studies or prevalence studies will 
inform this rating of certainty.(24, 25)
 
Similarly the certainty of the evidence regarding the 
estimates of the treatment effects of cryotherapy and other treatments should influence 
the overall certainty.  Applying GRADE for interventions, the certainty in the estimates for 
the effects of cryotherapy - coming from observational studies with high risk of bias - was 
very low (Figure 4, step 2).(13)  Persistence of CIN 2-3 in false negatives was estimated as 
approximately 70% based on moderate certainty evidence from longitudinal prognostic 
observational studies. Thus, step 2 in Figure 4 involves a rating of the certainty in the 
estimates when going from the test results to important outcomes.  Because the authors of 
the cervical cancer guideline had very low certainty in some of the steps that were part of 
the linked bodies of evidence, they rated the overall certainty as very low.(14)  
 
In addition, the rating of directness must include an assessment of the degree to which the 
impact of the test on patients occurs solely through the consequences of classification as 
true negative, false positive, true positive or false negative.  Tests may impact on patient 
outcomes where they are less invasive, can be delivered in different settings, care pathways 
or at different time points in the course of disease, or where they provide additional 
information which can change adherence or the nature of the intervention given (1, 5-7). 
For example, point of care testing that have the potential to speed up decision-making, 
enabling patients to access appropriate treatment faster and reduce anxiety waiting for 
results.  A linked evidence evaluation that solely considers the consequences of treatment 
based on test results will not capture the benefits of using a quicker and more portable test, 
and potentially will be misleading (1, 5, 26). 
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Table 2 presents the layer 3 summary of findings (SoF) Table for tests based on the best 
available research evidence (layer 2 SoF Tables add direct estimates of the adverse 
consequences and inconclusive results from tests and certainty of those estimates to layer 1 
tables but is not provided here) and a link to an interactive summary of findings table in 
GRADE’s database of evidence profiles and evidence to decision frameworks 
(dbep.gradepro.org; also in the online appendix). Certainty estimates do not appear in the 
table 2 (layer 3) because their presentation would be inefficient (they are all very low). The 
explanations in the related text of the table provide the sources of evidence, assumptions 
made, and explanations.  Table 3 summarizes the different layers of GRADE SoF tables, what 
information each of them includes and who would develop or use the tables. 
 
For example, the guideline panel assumed mortality will decrease in true positives relative 
to those untreated due to treatment, and will increase in false negative due to late or 
missed diagnosis. It also assumed that there would be no mortality from cervical cancer in 
true negative and false positive; this, however, is a simplification because women may 
develop CIN 2-3 later in life. The decision analysis, based on the available evidence, applied 
a 70% natural persistence of CIN 2-3 and progression to cervical cancer in women who do 
not receive treatment.(20) 
 
Assumptions of the recurrence rates of CIN 2-3 were 5.3% after successful initial 
cryotherapy, 2.2% in CKC and 5.3% in LEEP. That is, for a pretest probability of 2% or 20,000 
for CIN 2-3 out of 1 million, when using human papilloma virus (HPV) test for diagnosis of 
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CIN 2-3 (pooled sensitivity 95% and pooled specificity 84%), there would be 19,000 TP and 
1,000 FN. If all of the 19,000 TP receive treatment and assuming 2.2% recurrence or 
persistence rate with CKC treatment, 18,582, out of the 19,000 women screened would be 
cured but 418 (2.2% of 19,000) would relapse with CIN2-3.  
 
On the other hand, the 1,000 FN will not receive treatment. Assuming 70% natural 
persistence of CIN 2-3 (30% natural regression), CIN 2-3 will persist in 700 out of 1,000 FN. 
Based on the available observational data, approximately 2.5% of women who were not 
cured would progress to cervical cancer over a year. So, 2.5% out of 1118 (700 from FN + 
418 from TP) or 28 women will progress to cervical cancer. Then, out of the 19,000 TP and 
1,000 FN, a total of 1090 (418 + 700 - 28) recur or persist as CIN 2-3.  
 
Based on the available observational data, approximately 2.5% (350 out of 14,000 women 
with persistent CIN 2-3 with no treatment out of 1 million women screened) of those who 
were not cured would progress to cervical cancer over a year. So out of 1090, 28 women will 
develop cervical cancer. Based on a 71% mortality rate, 20 out of the 28 will die from 
cervical cancer. Other evidence suggested that no major bleeding would occur in the test 
negatives (both TN and FN) as they were not treated, but a small proportion of women 
(0.03%) would experience a major bleed with cryotherapy, as would 0.9% of women treated 
with CKC based on reported proportions in single arm studies.  
 
This modeling was conducted for each of the pathways in Figure 3 and results finally 
aggregated in a modified layer 3 SoF Table (Table 2).  Table 2 summarizes all effects by 
outcome for each test-screen strategy to allow balancing the benefits and harms. In 
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situations when circumstances change and a health status determines subsequent 
outcomes, more complex modelling will be beneficial to guideline developers and users.  
 
4. How do the certainty ratings of the linked evidence influence the overall rating of the 
certainty of the evidence  
Having realized that each link in the evidence can – and often does - lower the overall 
certainty one has in the evidence for each outcome, there are two viable options for 
describing an overall rating of the certainty of the evidence for each outcome. 
 
Option 1.  Evaluate which bodies of linked evidence are critical for decision-making and base 
the overall rating of the certainty for population important outcomes on the lowest 
certainty of these bodies of evidence.  For example, if a panel decided that both the natural 
history of the disease and efficacy of cryotherapy were critical for the decision, despite high 
certainty of the evidence of the estimates of test accuracy for TP and FN and moderate 
confidence in TN and FP, the recommendation would be associated with a rating of very low 
certainty for each of the outcomes of interest.  The frequency and importance with which 
an outcome occurs will determine whether or not linked evidence is critical to decision-
making. This is the approach the guideline panel on cervical cancer screening and treatment 
took by rating the overall certainty as very low.  An advantage of this approach is that it is 
most consistent with GRADE’s focus on outcomes that are critical to decision-making.  
 
Option 2.  Present the evidence from test accuracy and linked evidence separately without 
assigning an overall rating of certainty.  Using this approach, the certainty of the evidence 
for all elements would be described separately. For example, in the cervical cancer 
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screening and treatment guidelines, the recommendation would be accompanied by a 
rating of the certainty for the test accuracy (moderate certainty), the prognostic evidence 
(very low certainty) and the effects of therapy (e.g. very to low certainty for cryotherapy) 
without an overall rating of the certainty.   
 
Despite being more complex, we suggest using option 1 as preferred approach: providing an 
overall rating in the certainty across the elements of the linked evidence critical for decision-
making.  Usually and justifiably, certainty of the evidence that results from linking test 
accuracy evidence with people important outcomes will result in low or very low certainty of 
the evidence. This is the reason why guideline panels and other decision makers should be 
cautious when they use evidence of test accuracy as the basis for recommendations or 
decision. Further work will inform how users of GRADE’s summaries of a body of linked 
evidence and recommendations will appropriately integrate ratings of certainty and how to 
improve this presentation. 
 
5. When is evidence about accuracy sufficient to make a decision? 
Comprehensively (re)evaluating all evidence that informs the consequences of testing 
requires time and resources.  Informed decisions require, however, transparent 
presentations of the considerations influencing the recommendations and the certainty in 
the underlying evidence.  
 
If the accuracy of one test is very similar or superior to another test and there is no shift in 
the type of people or patients classified by the test, and it is also less expensive, easier to 
use, or comes with less harm, guideline panels can confidently recommend the test without 
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explicit consideration of downstream consequences. For example, the use of a shortened 
version of a psychological test, e.g. mini mental exam, that has fewer items but the same 
accuracy would save time without adverse consequences. Using computed tomography or 
magnetic resonance for presumed cerebrospinal fluid obstruction or lesions of the posterior 
fossa instead of an air encephalogram, a technique used before the arrival of modern 
imaging, provides greater accuracy and fewer risks. In such situations, panels can omit 
modeling the effects on health outcomes and impact on other consequences of different 
accuracy. This issue is addressed elsewhere in detail.(27)
 
 
 
6. How can panels make recommendations about tests or care strategies involving tests 
A recommendation associated with a diagnostic question follows from an evaluation of the 
balance between the desirable and undesirable consequences of the test and subsequent 
management (Figure 1).(1)  When estimates of the consequences of the false positive, false 
negative, inconclusive results and complication rates with the alternative diagnostic 
strategies warrant high certainty, we can make strong inferences concerning the relative 
effects of a test on important outcomes.   Such situations are, however, rare; typically 
guideline panels will lower their overall certainty in the evidence when considering linked 
evidence. 
 
Box 1 describes three recommendations regarding the use of tests that rely on test accuracy 
and the approaches the guideline panel took to develop them. These three examples 
emphasize that careful consideration of the consequences, and ideally decision analysis, are 
required to develop recommendations.  
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The guideline panel that developed recommendations regarding skin prick testing in 
patients with cow milk allergy determined that for patients with a relatively low probability 
of the disease (approximately 10%) skin prick testing results in a large number of false 
positives leading to unnecessary anxiety and further testing. It also leads to missing about 
3% (33/1000 tested patients are false negatives) of patients who suffer from cow milk 
allergy with the risk of severe allergic reaction and death. The certainty in the estimates of 
accuracy was low because of risk of bias and unexplained inconsistency in the 23 evaluated 
studies.  Furthermore, the panel was uncertain about the links between tests results and 
patient outcomes and thus characterized the overall certainty as very low. The guideline 
panel making recommendations about serological testing for tuberculosis used pragmatic 
and quick modeling (sometimes characterized as “back of the envelope”), but still made its 
assumptions about consequences of test results transparent. 
 
6.1 GRADE Evidence to Decision frameworks 
GRADE has used decision tables that increase transparency of the decision-making 
process.(10, 28) Extensive work has informed the selection of criteria that influence the 
development of health care recommendations about tests. As evidence to decision (EtD) 
frameworks, these criteria have been further developed as part of the DECIDE project and 
are included in GRADE’s GRADEpro software (www.gradepro.org) together with the 
interactive SoF tables. (1, 29-31) We have described these frameworks in detail in the 16
th
 
article in this series (1).   
 
The purpose of the frameworks is to help guideline panels and other decision makers 
developing recommendations about the use of tests to move from evidence to 
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recommendations. The frameworks inform decision makers’ judgments about the desirable 
and undesirable consequences of the considered. The frameworks also ensure that panels 
consider important factors that determine a recommendation (criteria) by providing a 
concise summary of the best available evidence. They facilitate a structured discussion and 
identify reasons for agreement and disagreement. 
 
EtD frameworks should include one or more of the three layers of a SoF table for tests – and 
in particular a description of the expected health outcomes, ideally in a layer 3 SoF table 
(Table 2).  An alternative is a narrative summary, but whatever the nature of the summary it 
should be included and linked to the full GRADE evidence profile. The framework, or the 
background information, should include the decision analysis (Table 2). Other information 
listed in Table 2 can be included when guideline panels intend to achieve complete 
transparency about the recommendations they make.    
 
7. Conclusions 
GRADE has developed and applied a comprehensive framework for rating the certainty in 
test accuracy estimates from a body of evidence and linking this evidence to outcomes 
when studies directly evaluating the effects of testing on health outcomes are not available. 
Guideline panels and other decision makers should be cautious when they use evidence of 
test accuracy as the basis for recommendations or decision. The framework focuses on 
explicitly and transparently laying out the elements or bodies of evidence required to 
making the link.  Although the framework has facilitated the development of 
recommendations about tests for several guidelines (18, 21, 22, 32) and can be ready 
applied, further examples and future research in several areas addressing the assessment of 
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the certainty and the degree of modeling required will be necessary to move this field 
forward. 
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Figure 1. Linkage of testing, interventions and outcomes (6) 
 
 
 
 
  
Testing/ 
diagnosis
(Uncertainty due to baseline 
risk or pretest probability  
from prognostic studies and 
imperfect diagnostic accuracy 
studies) 
•symptoms, prognostic 
factors, tests, other 
diagnostic tests or 
strategies
Therapy, 
treatment, 
observation, 
management
• either evaluated directly or indirectly as 
linked evidence" 
Outcome
• actions, e.g. other tests, following 
the observed outocomes or 
monitoring - which may be directly 
investigated or based on 
assumptions from indirect evidence
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Figure 2.  Generic analytic framework for a test from (2) from the USPTF – screening here 
refers to the application of a test (reprinted with permission) 
 
 
 
Legend: numbers refer to key questions as follows: (1) Is there direct evidence that 
screening reduces morbidity and/or mortality? (2) What is the prevalence of disease in the 
target group? Can a high-risk group be reliably identified? (3) Can the screening test 
accurately detect the target condition? (a) What are the sensitivity and specificity of the 
test? (b) Is there significant variation between examiners in how the test is performed? (c) 
In actual screening programs, how much earlier are patients identified and treated? (4) Does 
treatment reduce the incidence of the intermediate outcome? (a) Does treatment work 
under ideal, clinical trial conditions? (b) How do the efficacy and effectiveness of treatments 
compare in community settings? (5) Does treatment improve health outcomes for people 
diagnosed clinically? (a) How similar are people diagnosed clinically to those diagnosed by 
screening? (b) Are there reasons to expect people diagnosed by screening to have even 
better health outcomes than those diagnosed clinically? (6) Is the intermediate outcome 
reliably associated with reduced morbidity and/or mortality? (7) Does screening result in 
adverse effects? (a) Is the test acceptable to patients? (b) What are the potential harms, and 
how often do they occur? (8) Does treatment result in adverse effects? 
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Figure 3. Analytical framework for alternative pathways to screen and treat for cervical 
cancer. See also: https://dbep.gradepro.org/profile/50952068-76AE-516A-9CA3-
5DEF08A61624 
 
 
 
HPV = human papilloma virus 
VIA = visual inspection with acetic acid 
Test + = True and false positive tests (not known when test is performed) 
Test - = True and false negatives (not known when test is performed) 
CKC = Cold knife conization 
Leep = Loop electrosurgical excision procedure 
Cryo = cryotherapy 
* Mortality from cervical cancer (including those detected with recurrence or unsuccessful 
treatment), incidence of cervical cancer (including those detected with recurrence or 
unsuccessful treatment), CIN 2-3, undetected CIN 2-3), cancers detected at treatment and 
complications of both necessary and unnecessary (false positives) treatment including major 
bleeding, premature deliver and infertility.  
 
Examples of outcomes and analysis (time frame 30 years) – simplified modeling: 
 
CIN 2-3 in HPV/CKC (both from recurrence and lack of detection) 
Total # of women with outcome in HPV +/-CKC: 1090 resulting from a 2.2% persistence rate 
after CKC (19,000 TP X 0.022 = 418) and 67% persistence (1,000 FN X 0.672 as a result of 
70% natural persistence rate minus cervical cancer and mortality from cervical cancer = 672) 
CIN 2 - 3 in asymptomatic women
n = 1,000,000
Pretest probability = 2%
HPV test
CIN 2 or 3 
detected (n= 
175,800; 19,000 TP & 
156,800 FP)
Treat             
(eligble for 
cryotherapy?)
Cryotherapy
Outcomes*
LEEP or CKC
Outcomes*
For CKC: Persistent CIN 2-3 
= TP * Rate of persistence 
* Efficacy*Progression to 
cervical cancer *  19,000 
TP X 0.022 = 418
CIN 2 or 3 not 
detected              
(n= 824,200; 823,200 
TN & 1,000 FN)
Natural history
n = 1000 FN * 
persistence
Outcomes*
Persistent CIN 2-3 = FN * 
Rate of persistence -
cervical cancer - mortality 
from cancer = 1,000 FN X 
0.672 = 672
VIA test
CIN 2 or 3 
detected (test 
positive, including 
true and false 
positives)
Treat             
(eligble for 
cryotherapy?)
Cryotherapy
Outcomes*
LEEP or CKC
Outcomes*
CIN 2 or 3 not 
detected                
(test negative, 
including true and 
false negatives)
Natural history
Outcomes*
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Cervical cancer 
CIN 2-3 = 20,000 (2% of 1,000,000) resulting from 19,000 TP and 1,000 FN  
TP=19,000 
FN=1,000 
19,000 TP X 0.00055 (based on a systematic review of treatment for CKC treatment and 
progression to cervical cancer) = 11 
1,000 FN X 0.0175 (from 70% natural persistence rate minus cervical cancer and mortality 
from cervical cancer and annual rate of progression to cervical cancer) 
= 17 
Total: 11+17=28 
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Figure 4. Linking test accuracy to patient important outcomes 
 
 
 
  
Apply GRADE
Domains for 
Diagnostic Test 
Accuracy Studies
TP
FP
TN      
FN
Test 
Accuracy 
Synthesis
Test 
Accuracy 
Certainty of 
evidence
Sensitivity
Specificity
S
T
U
D
IE
S
Very low
Low
Moderate
High ⊕⊕⊕⊕
⊕OOO
⊕⊕⊕O
⊕⊕OO
Assess linked 
evidence
Directness of 
the outcome
Lower the 
certainty for 
indirectness
Mortality
Morbidity
QoL
Harms
Resources
Other
Final 
Certainty of evidence for each 
outcome based on test accuracy 
and linked evidence for the 
development of recommendations 
and making decisions
Very low
Low
Moderate
High ⊕⊕⊕⊕
⊕OOO
⊕⊕⊕O
⊕⊕OO
Natural History
Patients will suffer from disease without 
being detected or suffer from symptoms and 
undergo repeat testing or testing for other 
disease that will happen at certain rate.  
SR required, full framework always needs to 
be developed. 
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Figure 5. Linked evidence ratings that influence the overall certainty of the evidence. 
 
 
 
 
CoE = certainty of evidence
CoE
Diagnostic test 
accuracy
⊕ ⊕ ⊕ ⊕
⊕ ⊕ ⊕ ⊝
⊕ ⊕ ⊝ ⊝
⊕ ⊝ ⊝ ⊝
CoE
Linked evidence
⊕ ⊕ ⊕ ⊕
⊕ ⊕ ⊕ ⊝
⊕ ⊕ ⊝ ⊝
⊕ ⊝ ⊝ ⊝
Final CoE
(per outcome)
⊕ ⊕ ⊕ ⊕
⊕ ⊕ ⊕ ⊝
⊕ ⊕ ⊝ ⊝
⊕ ⊝ ⊝ ⊝
Consider all outcomes
Recommendation
Studies that link (TP, FP, 
TN, FN) to patient-
important outcomes:
• Prognosis studies
• Treatment studies
(Preferably from a 
systematic review)
• Diagnostic studies 
(Preferably from a 
systematic review)
GRADE GRADE
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Table 1. Layer 1 SoF Table HPV compared to VIA for detection of cervical intraepithelial 
neoplasia in women at risk for cervical cancer – see 
https://dbep.gradepro.org/profile/50952068-76AE-516A-9CA3-5DEF08A61624 
for GRADEpro interactive Summary of Findings Table 
 
 
  
 
Patients or population: Women at risk of cervical cancer 
Settings: screening clinics across the world  
New Test: HPV                   Cut-off value: – 
Comparison Test: VIA  Cut-off value: – 
Purpose: Screen and treat 
Role: Replacement 
Reference Test: conization and biopsy 
 
Number of 
Participants 
(Studies) 
8921 
(5) 
Pooled Sensitivity 
HPV 
95% (95% CI: 84 to 98) Pooled Sensitivity VIA 69% (95% CI: 54 to 81) 
Pooled Specificity 
HPV  
84% (95% CI: 72 to 91) Pooled Specificity VIA 87% (95% CI: 79 to 92) 
    
Test Result 
Number of results in 1000 per 1,000,000 women tested 
Quality  
of the Evidence 
(GRADE) 
Baseline risk 2%1 
HPV VIA 
True positives (TP) 19 
(17 to 20) 
14  
(11 to 16) 
⊕⊕⊕⊕ 
high  
TP absolute difference 5 more 
False negatives 
(FN) 
1 
(0 to 3) 
6  
(4 to 9) 
FN absolute difference 5 less 
True negatives (TN) 823  
(706 to 892) 
853  
(774 to 902) 
⊕⊕⊕⊝ 
moderate2,3  
due to inconsistency 
TN absolute difference 30 less 
False positives 
(FP) 
157  
(88 to 274) 
127  
(78 to 206) 
FP absolute difference 30 more 
Reference: (15).  
Footnotes: 
1 Prevalence of 2% was assumed to be the average prevalence in a representative population, numbers are rounded and 
expressed as women per million to reflect the population estimates and help with understanding the modeling in table 2 
2 Estimates of HPV and VIA sensitivity and specificity were variable despite similar cut-off values; inconsistency could not be 
explained by quality of studies. This was a borderline judgment. We downgraded TN and FP.  This decision is considered in the 
context of other factors, in particular, imprecision. 
3 Wide CI for TN and FP that may lead to different decisions depending on which of the confidence limits is assumed. 
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Table 2. Layer 3 Summary of Findings Table describing population important outcomes (all certainty of evidence ratings are very low and 
therefore not included separately): see also: https://dbep.gradepro.org/profile/50952068-76AE-516A-9CA3-5DEF08A61624 
 
Outcomes (quality of evidence very low 
for all of the outcomes) 
Events in the screen-treat strategies for patient important outcomes 
(numbers presented per 1,000,000 women) 
HPV +/- 
CKC 
HPV +/-
LEEP 
HPV +/- 
Cryo 
VIA +/- 
CKC 
VIA +/- 
LEEP 
VIA +/- 
Cryo NO screen 
Mortality from cervical cancer 20 30 30 81 88 88 250 
Cervical Cancer Incidence 28 43 43 112 124 124 350 
CIN2-3 recurrence 1088 1677 1677 4328 4762 4762 13400 
Undetected CIN2-3 (FN) 1000 6000 N/A 
Major bleeding 1511 397 60 1210 318 48 0 
Premature delivery 712 575 610 670 560 588 500 
Major infections 156 225 24 125 180 19 0 
Minor infections 1649 1061 1139 1321 850 913 0 
Unnecessarily treated (FP) 157000 127000 N/A 
Cancer found at one time screening 2454 3168 N/A 
The overall CoE for each of these outcomes is very low ⊕⊝⊝⊝. Our lack of confidence in these effect estimates stems mainly from very low quality evidence for treatment effects 
and natural progression/history data. Outcomes are not exclusive of each other but listed even if occurring twice as part of another (cervical cancer and mortality) to facilitate decision-
making. Lighter cells (green) indicate more favorable estimates compared to darker (red) cells related to the option. 
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We assume no mortality from cervical cancer in true negative (TN) and false positive (FP). To calculate the mortality from cervical cancer, we assumed 250 deaths per 350 women with 
cervical cancer. These numbers are based on Eastern Africa age standardized rates of cervical cancer and mortality provided by  WHO at http://globocan.iarc.fr/  - Accessed 30 October 
2012) 
We assume no cervical cancer in TN or FP. To calculate cervical cancer incidence in women with persistent CIN 2/3, we assumed 350 cervical cancers per 14000 women who have 
persistent CIN 2/3 (i.e. FN).  This incidence is based on Eastern Africa age standardized rate of cervical cancer of 350 cervical cancers per 1000000 women, of whom 2% have CIN 2/3 
(20000 women with CIN 2/3, and a subsequent 30% regression for a total of 14000 with persistent CIN 2/3).   This data is available from WHO at http://globocan.iarc.fr/ - Accessed 30 
October 2012) 
We assume no CIN2/3 in TN and FP. Our calculations in the model are based on 70% natural persistence of CIN 2/3 with no treatment (30% regression) in FN. The incidence of cervical 
cancer and mortality are also subtracted from the CIN 2/3 in FN (see above for calculations). TP are treated and recurrence rates of CIN 2/3 are 5.3% in cryotherapy and LEEP, and 2.2% 
in CKC.  
We assumed major bleed would be 0 in TN and FN as they were not treated. We assumed that a proportion of 0.000339 of the population treated with cryotherapy, 0.002257 with LEEP, 
and 0.008585 with CKC, based on pooled proportions in observational studies with no independent controls, will have major bleeding. 
We assumed 5% population risk of premature delivery in 1% women who become pregnant.  Based on pooled meta-analysis of controlled observational studies, 0.001125 of the 
population treated with cryotherapy, 0.000925 with LEEP, and 0.001705 of the population treated with CKC will have premature delivery. 
We did not identify any data about the risk of infertility after treatment for CIN2+.  
We assumed major infection would be 0 in TN and FN as they were not treated. Based on pooled proportions from studies with no independent control 0.000135 of the population treated 
with cryotherapy 0.001279with LEEP, and 0.000888 with CKC will have major infection. 
We assumed minor infection would be 0 in TN and FN as they were not treated. Based on pooled proportions from studies with no independent control, 0.006473 of the population treated 
with cryotherapy, 0.006027 with LEEP, and 0.009368 with CKC will have minor infection. 
Cancers detected at screening was calculated as the average number of cancers detected when screening across all diagnostic studies which contributed to the DTA data for each 
comparison. 
No screen numbers were calculated using the same assumptions above for FN, with the exception of premature delivery which was baseline risk in the population. 
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Table 3. GRADE SoF tables for test accuracy and linked evidence 
GRADE SoF Layers Information included  End users  
One Summarize the results of test 
accuracy reviews and 
certainty of those estimates. 
Layer 1 is usually used by 
systematic reviewer authors.  
Two Summarize the results of test 
accuracy reviews (layer 1) in 
addition to estimates of the 
direct adverse 
consequences, inconclusive 
results and certainty of those 
estimates. 
Layer 2 includes assumptions 
about consequences for 
patient important outcomes  
Three Summarize the modeled 
effects of performing the 
Layer 3 should be used by 
guideline developers or 
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test on important outcomes 
based on the best available 
research evidence. 
other decision-makers. 
Systematic reviewers of test 
accuracy would require 
additional information about 
the linked evidence and 
modeling. 
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Highlights 
GRADE has developed and applied a comprehensive framework to evaluate the certainty of the 
evidence when direct evidence of the effect of testing on outcomes is not available and linked 
evidence that connects test accuracy to downstream consequences is required for decision-
making. Ideally, this linked evidence comes from systematic reviews is that informs analytical 
frameworks for questions related to tests. 
What this adds to what is known? 
Application of GRADE’s approach requires guideline developers to rate their certainty in each 
element of the linked evidence that is required for decision-making.  
What are the implications, what should change now? 
Further research should address ways to arrive at, for each critical or important outcome and 
across outcomes, ratings of the certainty derived from the linked sources of evidence. This will 
often require formal modelling and assessing the certainty in the models. 
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